Brian Patrick Peppers
Research Subjects
Brian Patrick Peppers has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Robert Hostoffer
WVU Medicine Children’s
4 shared publicationsTheodore Sher
WVU Medicine Children’s
4 shared publications- Robert Hostoffer
Allergy/Immunology Associates Inc, Cleveland, Ohio
3 shared publications Haig Tcheurekdjian
Adult and Pediatric ACGME Osteopathic Recognized Allergy and Immunology Fellowship, University Hospitals, Cleveland Medical Center, Cleveland, Ohio
2 shared publicationsTracey Bonfield
Department of Immunology, Case Western Reserve University, Mayfield Heights, OH, United States
2 shared publications- Aaron Shmookler
Department of Pathology and Laboratory Medicine University of Kentucky School of Medicine Lexington Kentucky USA
1 shared publication
Latest Publications
- 9 April 2026
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 41 (10) , S133-S138
Standardizing Safe Cefazolin Use in Total Joint Arthroplasty: A Multidisciplinary Triage Protocol
- 9 April 2026
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 41 (10) , S133-S138
Standardizing Safe Cefazolin Use in Total Joint Arthroplasty: A Multidisciplinary Triage Protocol
- Open Access
- 1 June 2023
- Published by SAGE Publications in European Journal of Inflammation
- Vol. 21
Mannose binding lectin deficiency and COVID-19 rates of thrombosis and mortality: Partial protection by immunodeficiency
Objective: The purpose of this study is to determine the effects of COVID-19 infection on individuals with mannose binding lectin deficiency. Methods: An electronic medical records search was conducted for MBL deficiency and COVID-19 positive tests from March 2020-August 2022. Individualized chart analysis was conducted and statistical analysis was performed. Results: Thirty-three people in WVU medicine health system carry a diagnosis of mannose binding lectin deficiency and were diagnosed with COVID-19. The mean age of this cohort was 41 years. Seven individuals had severe enough symptoms to lead to an emergency department visit. One person was hospitalized. MBL deficient individuals had 7 times the odds of hospitalization ( p = .1506, OR 7.06 (CI 1.117-44.52)) compared to the general public. There was zero mortality among the MBL deficient population. None of the patients reported thrombosis or blood clots. Conclusion: This retrospective cross-sectional analysis of those with known MBL deficiency and COVID-19 infection suggest a lower risk of fatalities and thrombotic events in this cohort. There was however a higher odds ratio of hospitalization compared to the general public, although this was not statistically significant.
- 1 June 2023
- Published by SAGE Publications in European Journal of Inflammation
- Vol. 21
Open AccessMannose binding lectin deficiency and COVID-19 rates of thrombosis and mortality: Partial protection by immunodeficiency
Objective: The purpose of this study is to determine the effects of COVID-19 infection on individuals with mannose binding lectin deficiency. Methods: An electronic medical records search was conducted for MBL deficiency and COVID-19 positive tests from March 2020-August 2022. Individualized chart analysis was conducted and statistical analysis was performed. Results: Thirty-three people in WVU medicine health system carry a diagnosis of mannose binding lectin deficiency and were diagnosed with COVID-19. The mean age of this cohort was 41 years. Seven individuals had severe enough symptoms to lead to an emergency department visit. One person was hospitalized. MBL deficient individuals had 7 times the odds of hospitalization ( p = .1506, OR 7.06 (CI 1.117-44.52)) compared to the general public. There was zero mortality among the MBL deficient population. None of the patients reported thrombosis or blood clots. Conclusion: This retrospective cross-sectional analysis of those with known MBL deficiency and COVID-19 infection suggest a lower risk of fatalities and thrombotic events in this cohort. There was however a higher odds ratio of hospitalization compared to the general public, although this was not statistically significant.
- Open Access
- 10 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e27846
A 14-Year-Old Female With Several-Week History of Rash, Worsening Diffuse Arthralgias, and Fevers
Macrophage activation syndrome (MAS) as the initial presentation of systemic juvenile idiopathic arthritis (sJIA) is an uncommon and difficult diagnosis to ascertain. However, it remains critical to establish the diagnosis since MAS is a potentially life-threatening systemic inflammatory condition. Prompt recognition can lead to early initiation of treatment with corticosteroids and overall improved outcomes. Here, we present a case of a 14-year-old female with MAS as the initial manifestation of sJIA.
- 10 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e27846
Open AccessA 14-Year-Old Female With Several-Week History of Rash, Worsening Diffuse Arthralgias, and Fevers
Macrophage activation syndrome (MAS) as the initial presentation of systemic juvenile idiopathic arthritis (sJIA) is an uncommon and difficult diagnosis to ascertain. However, it remains critical to establish the diagnosis since MAS is a potentially life-threatening systemic inflammatory condition. Prompt recognition can lead to early initiation of treatment with corticosteroids and overall improved outcomes. Here, we present a case of a 14-year-old female with MAS as the initial manifestation of sJIA.
- Open Access
- 1 July 2022
- Published by Scholar, LLC in Scholar: Pilot and Validation Studies
- Vol. 3 (1) , 1
Medical Perspectives and Validation Studies
- 1 July 2022
- Published by Scholar, LLC in Scholar: Pilot and Validation Studies
- Vol. 3 (1) , 1
Open AccessMedical Perspectives and Validation Studies
- Open Access
- 1 January 2022
- Published by SAGE Publications in Allergy & Rhinology
- Vol. 13
Serial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West Virginia
Purpose: The rapid spread of SARS-CoV-2, the virus that is responsible for causing COVID-19, has presented the medical community with another example of when convalescent plasma (CP) is still used today. The ability to standardize CP at the onset of a pandemic is unlikely to exist in a reliable and uniformly reproducible way. We hypothesized that CP of unknown strength given in a serial manner will promote health and reduce mortality in those inflicted with COVID-19. Methods: Participants were given up to 8 CP-units depending on their condition upon entry into the study and their response. Results: 102 out of 117 participants were given CP. The earlier a participant received CP corelated with survival (p = 0.0004). The number of CP-units given, throughout all the clinical severities, was not significant with outcomes, p = 0.3947. A higher number of CP-units given to the severe/critical participants (without biological immunosuppressants or restrictive lung disease) did correlate with survival p = 0.0116 (2.8 vs. 2 units). Lower platelets on admission corelated with mortality. Platelet levels increase correlated with CP infusions p < 0.0001. Conclusion: This study supports the serial use of CP of unknown strength based on clinical response for those infected with COVID-19. The use of 3–4 units of CP was found to be statistically significant for survival for severe and critical participants without restrictive lung disease and chronic biological immunosuppression. Increased platelet levels after CP infusions supports that CP is promoting overall health regardless of outcomes.
- 1 January 2022
- Published by SAGE Publications in Allergy & Rhinology
- Vol. 13
Open AccessSerial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West Virginia
Purpose: The rapid spread of SARS-CoV-2, the virus that is responsible for causing COVID-19, has presented the medical community with another example of when convalescent plasma (CP) is still used today. The ability to standardize CP at the onset of a pandemic is unlikely to exist in a reliable and uniformly reproducible way. We hypothesized that CP of unknown strength given in a serial manner will promote health and reduce mortality in those inflicted with COVID-19. Methods: Participants were given up to 8 CP-units depending on their condition upon entry into the study and their response. Results: 102 out of 117 participants were given CP. The earlier a participant received CP corelated with survival (p = 0.0004). The number of CP-units given, throughout all the clinical severities, was not significant with outcomes, p = 0.3947. A higher number of CP-units given to the severe/critical participants (without biological immunosuppressants or restrictive lung disease) did correlate with survival p = 0.0116 (2.8 vs. 2 units). Lower platelets on admission corelated with mortality. Platelet levels increase correlated with CP infusions p < 0.0001. Conclusion: This study supports the serial use of CP of unknown strength based on clinical response for those infected with COVID-19. The use of 3–4 units of CP was found to be statistically significant for survival for severe and critical participants without restrictive lung disease and chronic biological immunosuppression. Increased platelet levels after CP infusions supports that CP is promoting overall health regardless of outcomes.
- Open Access
- 1 December 2021
- Published by Scholar, LLC in Scholar: Pilot and Validation Studies
- Vol. 2 (2) , 1
Highlighted articles
- 1 December 2021
- Published by Scholar, LLC in Scholar: Pilot and Validation Studies
- Vol. 2 (2) , 1
Open AccessHighlighted articles
- Open Access
- 1 July 2021
- Published by Scholar, LLC in Scholar: Pilot and Validation Studies
- Vol. 2 (1) , 1
Promoting health, making time and systemic changes
- 1 July 2021
- Published by Scholar, LLC in Scholar: Pilot and Validation Studies
- Vol. 2 (1) , 1
Open AccessPromoting health, making time and systemic changes
- Open Access
- 1 November 2020
- Published by Scholar, LLC in Scholar: Pilot and Validation Studies
- Vol. 1 (2) , 1
Returning to the Basics During a Crisis
- 1 November 2020
- Published by Scholar, LLC in Scholar: Pilot and Validation Studies
- Vol. 1 (2) , 1
Open AccessReturning to the Basics During a Crisis
- 1 January 2020
- Published by Scholar, LLC in Scholar: Pilot and Validation Studies
- Vol. 1 (1) , 1-3
A Time of Reflection and New Beginnings
Article Citation: Brian P. Peppers (2020) A Time of Reflection and New Beginnings. Scholar: Pilot and Validation Studies: January 2020, Vol. 1, No. 1, pp. 1-3. https://doi.org/10.32778/SPVS.71366.2020.1
- 1 January 2020
- Published by Scholar, LLC in Scholar: Pilot and Validation Studies
- Vol. 1 (1) , 1-3
A Time of Reflection and New Beginnings
Article Citation: Brian P. Peppers (2020) A Time of Reflection and New Beginnings. Scholar: Pilot and Validation Studies: January 2020, Vol. 1, No. 1, pp. 1-3. https://doi.org/10.32778/SPVS.71366.2020.1
- 17 May 2019
- Published by Springer Nature
- p. 593-600
Non-IgE Food Immunological Diseases